MX349827B - Compuestos que contienen nitrogeno y su uso. - Google Patents

Compuestos que contienen nitrogeno y su uso.

Info

Publication number
MX349827B
MX349827B MX2013015079A MX2013015079A MX349827B MX 349827 B MX349827 B MX 349827B MX 2013015079 A MX2013015079 A MX 2013015079A MX 2013015079 A MX2013015079 A MX 2013015079A MX 349827 B MX349827 B MX 349827B
Authority
MX
Mexico
Prior art keywords
containing compounds
nitrogen containing
compounds
preventing
formula
Prior art date
Application number
MX2013015079A
Other languages
English (en)
Other versions
MX2013015079A (es
Inventor
Bhagwat Sachin
Jagdishwar Patil Vijaykumar
Tadiparthi Ravikumar
Birajdar Satish
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2013015079A publication Critical patent/MX2013015079A/es
Publication of MX349827B publication Critical patent/MX349827B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la fórmula (I): (ver Fórmula) su preparación y su uso en la prevención o el tratamiento de infecciones bacterianas.
MX2013015079A 2011-09-13 2012-09-11 Compuestos que contienen nitrogeno y su uso. MX349827B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2582MU2011 2011-09-13
PCT/IB2012/054706 WO2013038330A1 (en) 2011-09-13 2012-09-11 Nitrogen containing compounds and their use

Publications (2)

Publication Number Publication Date
MX2013015079A MX2013015079A (es) 2014-01-24
MX349827B true MX349827B (es) 2017-08-14

Family

ID=47116128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015079A MX349827B (es) 2011-09-13 2012-09-11 Compuestos que contienen nitrogeno y su uso.

Country Status (13)

Country Link
US (3) US8754102B2 (es)
EP (1) EP3052497B1 (es)
JP (2) JP6114275B2 (es)
KR (1) KR101680933B1 (es)
CN (1) CN103781787B (es)
AU (1) AU2012310136B2 (es)
BR (1) BR112014003476A2 (es)
CA (1) CA2846107C (es)
ES (1) ES2640520T3 (es)
MX (1) MX349827B (es)
RU (1) RU2569307C1 (es)
WO (1) WO2013038330A1 (es)
ZA (1) ZA201308930B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
ES2640520T3 (es) * 2011-09-13 2017-11-03 Wockhardt Limited Compuestos que contienen nitrógeno y su uso
SG11201406123TA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
TW201343646A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 異□唑β－內醯胺酶抑制劑
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
WO2013180197A1 (ja) 2012-05-30 2013-12-05 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規β－ラクタマーゼ阻害剤とその製造法
JPWO2014069351A1 (ja) * 2012-11-01 2016-09-08 株式会社カネカ 光学活性二環式ウレア化合物の製造方法
US9567335B2 (en) * 2013-03-08 2017-02-14 Wockhardt Limited Process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
NZ711329A (en) * 2013-03-08 2016-06-24 Wockhardt Ltd A process for preparation of (2s, 5r)- sulfuric acid mono-{ [(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
NZ718009A (en) 2013-09-24 2018-03-23 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
AU2014333436A1 (en) * 2013-10-11 2016-05-05 Wockhardt Limited Nitrogen containing compounds and their use
CN106132411A (zh) * 2013-10-22 2016-11-16 沃克哈特有限公司 包含抗菌剂的药物组合物
CN105980385B (zh) * 2014-02-03 2018-01-09 沃克哈特有限公司 制备(2s,5r)‑1,6‑二氮杂‑二环[3.2.1]辛烷‑2‑腈‑7‑氧代‑6‑(磺氧基)‑单钠盐的方法
WO2015125031A1 (en) * 2014-02-20 2015-08-27 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
KR20160126004A (ko) * 2014-03-14 2016-11-01 욱크하르트 리미티드 항세균제를 포함하는 제약학적 조성물
WO2015148379A1 (en) 2014-03-24 2015-10-01 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
IN2014MU01192A (es) 2014-03-29 2015-10-02 Wockhardt Ltd
CN107980000A (zh) * 2014-04-18 2018-05-01 沃克哈特有限公司 包含抗菌剂的药物组合物
WO2015159167A1 (en) * 2014-04-18 2015-10-22 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
DK3221313T3 (en) 2014-11-17 2019-04-08 Entasis Therapeutics Ltd COMBINATION THERAPY FOR TREATING INFECTIONS WITH RESISTANT BACTERIA
TWI691499B (zh) 2014-12-05 2020-04-21 日商明治製菓藥業股份有限公司 二氮雜雙環辛烷衍生物之結晶及安定的凍結乾燥製劑的製造法
CA3000087A1 (en) 2015-10-02 2017-04-06 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
CN106749242B (zh) * 2015-11-23 2021-04-02 上海医药工业研究院 阿维巴坦中间体的制备方法
KR102537340B1 (ko) 2016-09-16 2023-05-26 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
TW201831482A (zh) 2017-02-06 2018-09-01 法商木塔比利斯公司 新穎雜環化合物及其預防或治療細菌感染之用途
WO2018193368A1 (en) * 2017-04-18 2018-10-25 Wockhardt Limited Antibacterial compositions
MA48743A (fr) 2017-05-08 2020-04-08 Entasis Therapeutics Inc Composés et méthodes de traitement d'infections bactériennes
KR20200030584A (ko) 2017-07-21 2020-03-20 앤타바이오 에스에이에스 화합물
CN109400521B (zh) * 2017-08-18 2020-05-08 新发药业有限公司 一种改进的5r-苄氧氨基哌啶-2s-甲酸酯、其草酸盐的制备方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
CA3110111A1 (en) 2018-08-09 2020-02-13 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109870583B (zh) * 2019-04-15 2020-03-06 德阳市人民医院 急性胰腺炎相关的代谢物及其应用
WO2021165927A1 (en) 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents
EP4146650B1 (en) 2020-09-01 2026-01-21 Ningxia Academy of Agriculture and Forestry Sciences Beta-lactamase inhibitors and their preparation
EP4146651B1 (en) 2021-05-07 2026-03-04 Ningxia Academy of Agriculture and Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177099T1 (de) * 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
EP2921559A1 (en) * 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
ES2640520T3 (es) * 2011-09-13 2017-11-03 Wockhardt Limited Compuestos que contienen nitrógeno y su uso

Also Published As

Publication number Publication date
RU2014109447A (ru) 2015-11-10
EP3052497B1 (en) 2017-06-28
JP2016047853A (ja) 2016-04-07
US20150141394A1 (en) 2015-05-21
US20140088070A1 (en) 2014-03-27
ES2640520T3 (es) 2017-11-03
CN103781787B (zh) 2015-09-23
CN103781787A (zh) 2014-05-07
US8754102B2 (en) 2014-06-17
CA2846107C (en) 2016-06-21
BR112014003476A2 (pt) 2017-03-01
JP2014521739A (ja) 2014-08-28
WO2013038330A1 (en) 2013-03-21
AU2012310136B2 (en) 2016-07-07
US8969334B2 (en) 2015-03-03
AU2012310136A1 (en) 2013-12-19
US20150018312A1 (en) 2015-01-15
RU2569307C1 (ru) 2015-11-20
US9090616B2 (en) 2015-07-28
EP3052497A1 (en) 2016-08-10
CA2846107A1 (en) 2013-03-21
MX2013015079A (es) 2014-01-24
JP6114275B2 (ja) 2017-04-12
ZA201308930B (en) 2015-02-25
KR101680933B1 (ko) 2016-11-29
KR20140023401A (ko) 2014-02-26
NZ618286A (en) 2015-07-31

Similar Documents

Publication Publication Date Title
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
PH12012501841B1 (en) Anti-infective compounds
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PH12013502135A1 (en) Antimicrobial compounds and methods of making and using the same
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MY177344A (en) Compounds and their methods of use
PH12014500904B1 (en) Antibody formulations and methods
PH12015501609A1 (en) Phenicol antibacterials
PH12015501088A1 (en) Dimeric compounds
MX2016009248A (es) Compuestos que contienen nitrogeno y su uso como agentes antibacterianos.
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
MX2014007895A (es) Inhibidores de iap.
SG10201900541QA (en) Derivatives of xanthone compounds
MX2014006686A (es) Derivaods novedosos de pirrol.
PH12015500399A1 (en) Azaindolines
MX2015005753A (es) Agentes antimicrobianos.
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
PH12015500185A1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
IN2013MU03216A (es)
MX2013007055A (es) Derivados de sanglifehrina y metodos para su produccion.
IN2015DN02109A (es)
MX356102B (es) Compuestos y métodos para tratar leucemia.

Legal Events

Date Code Title Description
FG Grant or registration